Getting a medical device or pharmaceutical product into markets outside its home country is rarely just about clinical data or engineering performance. Regulators in the United States, European Union, China, and elsewhere treat the language of labeling, instructions for use, technical files, and clinical documentation as part of the product itself. When that language fails, the consequences move quickly from paperwork delays to stalled market entry, corrective actions, or worse.
The bar is high because the stakes are. A 2009 case involving knee prosthesis documentation in Berlin showed how mistranslations led to 47 patients receiving implants in an unintended manner. In 2017, the FDA issued a warning letter after translation problems around active pharmaceutical ingredient naming contributed to a product containing dexamethasone being labeled as hydrocortisone. These are not isolated footnotes. Terminology inconsistencies between language versions remain a documented reason for extended review timelines, requests for additional information, and rejected submissions under both FDA rules and the EU Medical Device Regulation (MDR).
Under EU MDR and IVDR, manufacturers must supply labeling and instructions for use in the official language of every member state where the device is placed on the market, with consistent terminology across all versions. The FDA, through 21 CFR Parts 801 and 809, requires labeling that is understandable to intended users and holds manufacturers accountable for the accuracy of any translated versions. Documents submitted in a language other than English must include a complete English translation accompanied by a signed accuracy statement. Approximate equivalents for terms such as “sterile,” “single-use,” or “contraindication” can trigger clarification requests or rejection because those words carry specific legal weight.
The difficulty compounds when products move across multiple jurisdictions. A phrase that works cleanly in English may lack a precise counterpart in another language, or a regulatory concept may need re-expression to match local guidance. Frequent product updates force re-translation of already-approved content, raising the risk of version drift. Using separate vendors for different markets without a shared glossary or translation memory often produces exactly the inconsistencies that notified bodies and FDA reviewers flag. Machine translation alone does not solve this; regulatory and safety-critical content still requires review and validation by qualified human linguists who understand both the source science and the target regulatory framework.
Patient safety sits at the center. An unclear warning, a shifted dosage instruction, or an ambiguous contraindication can lead to use errors. Beyond safety, the commercial cost of remediation—delays measured in months of lost revenue, field safety corrective actions, brand damage, and heightened scrutiny on future submissions—routinely exceeds the investment required for controlled terminology, qualified linguists, and proper quality processes from the start.
What separates reliable medical translation from ordinary language work is therefore not fluency alone. It is subject-matter expertise, locked terminology databases that preserve regulatory meaning across documents and languages, multi-stage review by people who know both the clinical domain and the relevant regulations, and rigorous version control. The process must treat every language version as part of a single, coherent compliance package rather than a set of independent files.
Artlangs Translation has spent more than two decades building precisely this capability. With proficiency across 230+ languages, a network of over 20,000 professional translators, and a track record of successful medical and pharmaceutical projects, the company supports the full range of documentation needed for overseas registration. Its work extends beyond pure text translation into video localization, short-drama subtitle localization, game localization, multilingual dubbing for short dramas and audiobooks, and multilingual data annotation and transcription—services that increasingly intersect with digital health and training materials accompanying medical devices. For companies navigating the unforgiving requirements of global market entry, that combination of specialized medical experience and broad language coverage reduces the chance that a single word will stand between a product and the patients who need it.
